The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Inhibitors of alprazolam metabolism in vitro: effect of serotonin‐ reuptake‐inhibitor antidepressants, ketoconazole and quinidine.
Open accessAbstract
1. The biotransformation of the triazolobenzodiazepine alprazolam (ALP) to its hydroxylated metabolites (4‐OH‐ALP and alpha‐OH‐ALP) was evaluated in human, monkey, rat, and mouse liver microsomes. 2. In all species 4‐OH‐ALP was the principal metabolite, accounting for 84% of clearance in human microsomes compared with 16% for alpha‐OH‐ALP. 3. Among the serotonin‐specific reuptake inhibitors fluoxetine (FLU) and sertraline (SERT), and their respective demethylated metabolites norfluoxetine (NOR) and desmethylsertraline (DES), NOR was the most potent inhibitor (mean Ki for 4‐OH‐ALP formation in humans: 11 microM), FLU the weakest (Ki = 83 microM), with SERT and DES falling in between (Ki = 24 and 20 microM). 4. The in vitro data predict 29% inhibition of ALP clearance at mean FLU and NOR plasma concentrations of 77 ng ml‐1 and 72 ng ml‐1, respectively, after correction for liver:water partition ratios in the range of 12‐14. The observed mean degree of inhibition in a previous in vivo study was 21%. 5. Ketoconazole was a potent inhibitor of ALP metabolism in vitro (Ki = 0.046 microM), suggesting that ALP hydroxylation is mediated by the cytochrome P450‐3A sub‐family. Quinidine was a weak inhibitor (Ki = 626 microM).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Smith, R. B., & Kroboth, P. D. (1987) · Psychopharmacology · doi:10.1007/bf02439595 · Cited by 76
Cited by
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Self-citationRitonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
Clinical Pharmacokinetics of Sertraline
DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241150-00002 · Cited by 404
Metadata
- Authors
- von Moltke, L., Greenblatt, D., Cotreau‐Bibbo, M., Harmatz, J., & Shader, R.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1994-07
- Volume
- 38
- Issue
- 1
- Pages
- 23-31
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2016311788
- Cited by
- 161
- References
- 2
- FWCI
- 17.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibitors of alprazolam metabolism in vitro: effect of serotonin‐ reuptake‐inhibitor antidepressants, ketoconazole and quinidine. https://app.cochat.ai/papers/10.1111/j.1365-2125.1994.tb04317.x
- The paper
- von Moltke, L., Greenblatt, D., Cotreau‐Bibbo, M., Harmatz, J., & Shader, R. (1994). Inhibitors of alprazolam metabolism in vitro: effect of serotonin‐ reuptake‐inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.1994.tb04317.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.